PPAB001

PPAB001 is a **novel bispecific antibody** that simultaneously targets **CD47** and **CD24**, two cell surface proteins implicated in immune evasion by cancer cells. The drug is designed to enhance macrophage-mediated phagocytosis of tumor cells and reprogram tumor-associated macrophages toward an anti-tumor (M1) phenotype. Preclinical studies have shown that PPAB001 significantly delays tumor growth in models of **triple-negative breast cancer (TNBC)**, especially when given in combination with the anti-PD-L1 antibody atezolizumab (Tecentriq), by upregulating the CXCL9/10-CXCR3 signaling axis and activating the JAK/STAT1 pathway. This dual blockade approach aims to maximize antitumor immune responses and overcome resistance to checkpoint inhibitors[1][3].